TNFRSF8 and mycosis fungoides: This would provide a mechanistic understanding of why CD30 expression is a negative prognostic marker in MF [31,50] and how the targeted depletion of CD30 expressing cells with brentuximab vedotin can induce clinical responses in patients whose malignant cells are CD30 negative [51,52].